Sacroiliac Joint Fusion Injections and RF Ablation Market To Reach $1.51 Billion By 2030

Sacroiliac Joint Fusion Injections and RF Ablation Market Growth & Trends

The global sacroiliac joint fusion injections and RF ablation market size is expected to reach USD 1.51 billion by 2030, expanding at a CAGR of 20.2% from 2024 to 2030, according to a new study by Grand View Research, Inc. Key market players are investing substantially in research & development (R&D) activities to create innovative and effective devices. This increase in R&D activities is expected to drive market growth over the coming years. In addition, the market is expected to grow further due to the increasing prevalence of bone disorders and ongoing technological advancements.

Increasing prevalence of lower back, buttock, groin, and lower extremity pain drives SI joint fusion market growth. These chronic and debilitating forms of pain have become alarmingly common, affecting a substantial portion of the global population. This trend poses significant challenges to healthcare systems and fuels demand for innovative solutions to alleviate suffering and restore mobility. According to the National Center for Biotechnology Information (NCBI) study published in December 2023, approximately 23% of adults globally experience chronic low back pain, and the recurrence rate within a year range from 24% to 80%. The lifetime back pain prevalence in adults reaches as high as 84%.

 Request a free sample copy or view report summary: Sacroiliac Joint Fusion Injections and RF Ablation Market Report

Sacroiliac Joint Fusion Injections and RF Ablation Market Report Highlights

• Based on indication, thedegenerative sacroilitis segment accounted for the largest revenue share in 2023 and is anticipated to grow at the fastest CAGR. The growth is attributed to the growing awareness about the condition, improving diagnostic capabilities for sacroiliac joint disorders, and a high prevalence of degenerative sacroiliitis

• Based on type, the diagnosis segment accounted for the largest market share in 2023. The growth is attributed to the accurate diagnosis and determining the appropriate treatment for sacroiliac joint pain

• Based on end-use, the hospitals segment accounted for the largest revenue share in 2023 owing to the higher volume of surgeries performed in hospitals and a growing preference for minimally invasive surgeries

• In 2023, North America dominated the overall market with a revenue share of 41.1% owing to advanced healthcare infrastructure, the presence of key companies, and growing reimbursement coverage

Sacroiliac Joint Fusion Injections and RF Ablation Market Segmentation

Grand View Research has segmented the global sacroiliac joint fusion injections and RF ablation market based on indication, type, end-use, and region:

Sacroiliac Joint Fusion Injections & RF Ablation Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Degenerative Sacroilitis

• Sacral Disruption

• Trauma

Sacroiliac Joint Fusion Injections & RF Ablation Type Outlook (Revenue, USD Million, 2018 - 2030)

• Diagnosis

• Treatment

Sacroiliac Joint Fusion Injections & RF Ablation End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Ambulatory Surgical Centers

• Others

Sacroiliac Joint Fusion Injections & RF Ablation Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Sweden

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Sacroiliac Joint Fusion Injections and RF Ablation Market

• SI-BONE, Inc.

• PainTEQ

• CornerLoc

• SIGNUS Medizintechnik GmbH

• Globus Medical

• Orthofix Medical, Inc.

• Life Spine, Inc.

• Camber Spine Technologies, LLC

• CoreLink Surgical

• Xtant Medical

• Surgalign Spine Technologies, Inc.

• Medtronic.